Industry News & Blogs
ZIOPHARM Oncology Inc Reports Positive Preliminary
NEW YORK, Feb. 13, 2012 -- ZIOPHARM Oncology, Inc. , a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer
Infection risk not increased with alemtuzumab : The Lancet Oncology
Infection risk not increased with alemtuzumab. By - Bryant Furlow
Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
< p > Roche Holding Ltd. ( < a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Hldg Ltd Spons' > RHHBY.PK < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 01, 2012 01:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Severin Schwan – Chief Executive
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications {– Study met
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE<sup>®</sup>
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Laryngeal Cancer Therapeutics Market is Forecast to Show Slow Growth Until 2019 - PR11793534
Popular Colorectal Cancer Drug May Cause Permanent Nerve Damage - 09/27/2011
Oxaliplatin, a platinum-based anticancer drug that’s made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends. The chemotherapy side effect, described by Johns Hopkins researchers in the
FDA Notifies Genentech of Violations at Avastin Plant - - BioPharm International
On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company?s South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA
FDA Removes Avastin Breast Cancer Indication - Pharmaceutical Technology
The breast cancer indication for Avastin has been revoked after FDA Commissioner Margaret A. Hamburg concluded that the drug has not been shown to be safe and effective for this use.
FDA blow for blockbuster Roche drug - FT.com
The US Food and Drug Administration has revoked approval for Roche’s blockbuster drug Avastin to treat breast cancer, dealing a blow to the company and disappointing health groups that have argued the drug has saved lives. Margaret Hamburg, FDA
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Refine by Content Type:
Refine by Source:
- www.thelancet.com (860)
- download.thelancet.com (241)
- www.medpagetoday.com (144)
- www.em-consulte.com (136)
- seekingalpha.com (118)
- www.biospace.com (98)
- www.aerzteblatt.de (55)
- www.genengnews.com (48)
- www.webmd.com (25)
- www.prlog.org (22)
- www.pharmaceutical-business-review.com (20)
- www.dddmag.com (20)
